Oxford Biomedica (LON:OXB) Posts Quarterly Earnings Results

Oxford Biomedica (LON:OXB) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported GBX (26.92) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 24.51% and a negative return on equity of 82.57%.

Here are the key takeaways from Oxford Biomedica’s conference call:

• OXB reported strong 2025 results with revenue up 33% to £170.9m and its first full-year operating EBITDA profit of £8.1m since the strategic refocus.
• The company says its commercial visibility is robust, with backlog up 36% to £204m and contracted client orders at £224m, covering ~60% of 2026 guidance and >80% when including risk‑adjusted pipeline items.
• OXB completed the acquisition of an FDA‑approved commercial-scale Durham facility, giving it an end‑to‑end U.S. manufacturing footprint that management says accelerated commercial deals (e.g., BMS) and expands capacity for late‑stage launches.
• 2026 guidance is for £220–240m revenue and ~10% full‑year operating EBITDA margin (H1 expected EBITDA‑lossy due to maintenance, tech transfers and Durham integration), with capex ~£50m for 2026–27 and medium‑term targets of 25–30% y/y growth and ≥20% EBITDA in 2027.
• Balance sheet strengthened with year‑end cash of £96.9m, net cash ~£55.4m, a £60m equity placing and a new Oaktree facility, which management says provides funding flexibility for network investment and ramp‑up.

Oxford Biomedica Stock Performance

OXB traded down GBX 14.10 during midday trading on Thursday, reaching GBX 591.90. The company had a trading volume of 508,083 shares, compared to its average volume of 601,630. The business has a 50-day moving average of GBX 747.49 and a two-hundred day moving average of GBX 665.24. The company has a quick ratio of 1.67, a current ratio of 1.89 and a debt-to-equity ratio of 322.11. Oxford Biomedica has a 1 year low of GBX 232.50 and a 1 year high of GBX 952. The company has a market cap of £715.44 million, a P/E ratio of -16.34 and a beta of 1.04.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Jefferies Financial Group initiated coverage on Oxford Biomedica in a research note on Monday. They issued a “buy” rating and a GBX 827 price target on the stock. Stifel Nicolaus reissued a “buy” rating and issued a GBX 950 target price on shares of Oxford Biomedica in a report on Wednesday, March 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a research note on Friday, January 9th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Oxford Biomedica currently has a consensus rating of “Moderate Buy” and an average target price of GBX 687.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.